New type of treatment for Crohn’s disease is approved by NICE

Ustekinumab (Stelara) has been recommended by NICE as an option for treating moderate to severe Crohn’s disease in adults who have had little or no response, or an intolerance to existing therapies. Crohn’s disease is an inflammatory bowel disease, and can affect any part of the digestive system. Symptoms can include stomach cramps, diarrhoea and fatigue. It is a chronic condition which means that is it lifelong. Ustekinumab works in a different way to existing treatments and is already recommended by NICE to treat psoriasis and psoriatic arthritis.  It is an innovative human monoclonal antibody treatment which binds to specific proteins